Current Research & Innovations

Pulmonary Fibrosis

• Exercise Capacity and Survival in Idiopathic Pulmonary Fibrosis — ( , )
• Interstitial Lung Disease and Pulmonary Fibrosis / AVONEX® Undergoing Multi-center Trial —AVONEX® (interferon beta-1a) to inhibit the decline in pulmonary function in patients with Idiopathic Pulmonary Fibrosis (IPF). (Larry Schulman, MD)
• Interstitial Lung Disease: Studying Biological and Social Factors That Determine Outcomes —This study aims to identify biological and social factors that may play a role in the survival of patients with diffuse parenchymal lung disease (interstitial lung disease). (David Lederer, MD)